Please Wait.....
Report
eClinical solutions Market By Product (Electronic Data Capture and Clinical Data Management Systems, Clinical Trial Management Systems, Randomization and Trial Supply Management, Electronic Clinical Outcome Assessment, Electronic Trail Master Files, Others), By Delivery Mode (Web-hosted, On-premise, Cloud-based), By Clinical Trial Phase (Phase I, Phase II, Phase III, Phase IV), By End User (Pharmaceutical and Biopharmaceutical Companies, Contract Research Organizations, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031
Market Report I 2022-07-01 I 358 Pages I Allied Market Research
The global eClinical solutions market was valued at $6,816.17 million in 2021, and is estimated to reach $21,502.95 million by 2031, growing at a CAGR of 12.2% from 2022 to 2031.
eClinical solutions are software, which are used for effective management, and integration of data generated during clinical trials. It offers set of tools to effectively plan, manage, track clinical study portfolio and create insights. The major factors that drive the growth of the eClinical solutions market are decrease in time cycle, reduction in data duplication, and additional efforts taken by team carrying out clinical trial for sorting and integrating the data.
In addition, eClinical solutions accelerates decision making as data is sorted and integrated by the software itself. It is a key trend of the market, which is expected to fuel the growth of the market during the forecast period. These solutions creates the demographic charts, mapping and comprehensive analytics that answer clinical and operational questions with speed and accuracy. Thus by centralizing data issues, errors are identified sooner and decision making process gets accelerated. Furthermore, significant surge in technological advancement is also one leading factors of this market as paper work takes much time, thus, managing enormous data makes individual frustrated. By using advanced technological solutions it becomes easier to manage data for the team carrying out clinical trials. Moreover, emerging markets are becoming a hub for the growth of eClinical solutions utilization owing to rise in the number of clinical trials. There are lot of opportunities for the market players to expand their business across developing economies due to availability of resources at lower rate and less regulatory policies for drug development.
Augmentation of data, government initiatives for making better healthcare services assists the market growth in emerging markets. However, eClinical solutions required high initial capital cost and regular maintenance attempts, which impede the market growth. The eClinical solutions market is segmented on the basis of product, delivery mode, clinical trials, end user, and region. On the basis of product, the market is categorized into electronic data capture (EDC) &clinical data management systems (CDMS), clinical trial management systems (CTMS), randomization & trial supply management (RTMS), electronic clinical outcome assessment (eCOA), electronic trial master file (eTMF), and others.
On the basis of delivery mode, the market is segmented as web-hosted, on-premise, and cloud-based. On the basis of clinical trials, the market is segmented as Phase I, Phase II, Phase III, and Phase IV. On the basis of end users, the market is segmented into pharmaceutical & biopharmaceutical companies, contract research organizations, and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America, the Middle East, and Africa (LAMEA).
The major players profiled in the report are Oracle Corporation, Parexel International Corporation (Calyx), DataTrak International, Inc., Dassault Systemes (Medidata Solution, Inc.), Clario, Signant Health (CRF Health Inc.), eClinical Solutions, Inc., IBM Watson Health, Advarra, Inc. (Bio-Optronics, Inc.), MaxisIT Inc., Anju Software, Inc. Veeva Systems, Saama Technologies, Inc., Medrio, Inc., Castor EDC, Mednet, and Business Systems Integration AG.
Key Benefits For Stakeholders
-This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the eClinical solutions market analysis from 2022to 2031 to identify the prevailing eClinical solutions market opportunities.
-The market research is offered along with information related to key drivers, restraints, and opportunities.
-Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
-In-depth analysis of the eClinical solutions market segmentation assists to determine the prevailing market opportunities.
-Major countries in each region are mapped according to their revenue contribution to the global market.
-Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
-The report includes the analysis of the regional as well as global eClinical solutions market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Delivery Mode
- Web-hosted
- On-premise
- Cloud-based
By Clinical Trial Phase
- Phase I
- Phase II
- Phase III
- Phase IV
By Product
- Clinical Trial Management Systems
- Randomization and Trial Supply Management
- Electronic Clinical Outcome Assessment
- Electronic Trail Master Files
- Others
- Electronic Data Capture and Clinical Data Management Systems
By End User
- Pharmaceutical and Biopharmaceutical Companies
- Contract Research Organizations
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Advarra, Inc. (Bio Optronics, Inc.)
- Anju Software, Inc.
- Business Systems Integration AG
- Castor EDC
- Clario
- Dassault Systemes (Medidata Solution, Inc.)
- DataTrak International, Inc.
- eClinical Solutions, Inc.
- IBM Watson Health
- MaxisIT Inc.
- MedNet Solutions
- Medrio, Inc.
- Parexel International Corporation (Calyx)
- Saama Technologies, Inc.
- Signant Health (CRF Health Inc.)
- veeva systems
- Oracle Corporation
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: ECLINICAL SOLUTIONS MARKET, BY PRODUCT
4.1 Overview
4.1.1 Market size and forecast
4.2 Electronic Data Capture and Clinical Data Management Systems
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Clinical Trial Management Systems
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Randomization and Trial Supply Management
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 Electronic Clinical Outcome Assessment
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
4.6 Electronic Trail Master Files
4.6.1 Key market trends, growth factors and opportunities
4.6.2 Market size and forecast, by region
4.6.3 Market analysis by country
4.7 Others
4.7.1 Key market trends, growth factors and opportunities
4.7.2 Market size and forecast, by region
4.7.3 Market analysis by country
CHAPTER 5: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE
5.1 Overview
5.1.1 Market size and forecast
5.2 Web-hosted
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 On-premise
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Cloud-based
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
CHAPTER 6: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE
6.1 Overview
6.1.1 Market size and forecast
6.2 Phase I
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Phase II
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Phase III
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
6.5 Phase IV
6.5.1 Key market trends, growth factors and opportunities
6.5.2 Market size and forecast, by region
6.5.3 Market analysis by country
CHAPTER 7: ECLINICAL SOLUTIONS MARKET, BY END USER
7.1 Overview
7.1.1 Market size and forecast
7.2 Pharmaceutical and Biopharmaceutical Companies
7.2.1 Key market trends, growth factors and opportunities
7.2.2 Market size and forecast, by region
7.2.3 Market analysis by country
7.3 Contract Research Organizations
7.3.1 Key market trends, growth factors and opportunities
7.3.2 Market size and forecast, by region
7.3.3 Market analysis by country
7.4 Others
7.4.1 Key market trends, growth factors and opportunities
7.4.2 Market size and forecast, by region
7.4.3 Market analysis by country
CHAPTER 8: ECLINICAL SOLUTIONS MARKET, BY REGION
8.1 Overview
8.1.1 Market size and forecast
8.2 North America
8.2.1 Key trends and opportunities
8.2.2 North America Market size and forecast, by Product
8.2.3 North America Market size and forecast, by Delivery Mode
8.2.4 North America Market size and forecast, by Clinical Trial Phase
8.2.5 North America Market size and forecast, by End User
8.2.6 North America Market size and forecast, by country
8.2.6.1 U.S.
8.2.6.1.1 Market size and forecast, by Product
8.2.6.1.2 Market size and forecast, by Delivery Mode
8.2.6.1.3 Market size and forecast, by Clinical Trial Phase
8.2.6.1.4 Market size and forecast, by End User
8.2.6.2 Canada
8.2.6.2.1 Market size and forecast, by Product
8.2.6.2.2 Market size and forecast, by Delivery Mode
8.2.6.2.3 Market size and forecast, by Clinical Trial Phase
8.2.6.2.4 Market size and forecast, by End User
8.2.6.3 Mexico
8.2.6.3.1 Market size and forecast, by Product
8.2.6.3.2 Market size and forecast, by Delivery Mode
8.2.6.3.3 Market size and forecast, by Clinical Trial Phase
8.2.6.3.4 Market size and forecast, by End User
8.3 Europe
8.3.1 Key trends and opportunities
8.3.2 Europe Market size and forecast, by Product
8.3.3 Europe Market size and forecast, by Delivery Mode
8.3.4 Europe Market size and forecast, by Clinical Trial Phase
8.3.5 Europe Market size and forecast, by End User
8.3.6 Europe Market size and forecast, by country
8.3.6.1 Germany
8.3.6.1.1 Market size and forecast, by Product
8.3.6.1.2 Market size and forecast, by Delivery Mode
8.3.6.1.3 Market size and forecast, by Clinical Trial Phase
8.3.6.1.4 Market size and forecast, by End User
8.3.6.2 France
8.3.6.2.1 Market size and forecast, by Product
8.3.6.2.2 Market size and forecast, by Delivery Mode
8.3.6.2.3 Market size and forecast, by Clinical Trial Phase
8.3.6.2.4 Market size and forecast, by End User
8.3.6.3 U.K.
8.3.6.3.1 Market size and forecast, by Product
8.3.6.3.2 Market size and forecast, by Delivery Mode
8.3.6.3.3 Market size and forecast, by Clinical Trial Phase
8.3.6.3.4 Market size and forecast, by End User
8.3.6.4 Italy
8.3.6.4.1 Market size and forecast, by Product
8.3.6.4.2 Market size and forecast, by Delivery Mode
8.3.6.4.3 Market size and forecast, by Clinical Trial Phase
8.3.6.4.4 Market size and forecast, by End User
8.3.6.5 Spain
8.3.6.5.1 Market size and forecast, by Product
8.3.6.5.2 Market size and forecast, by Delivery Mode
8.3.6.5.3 Market size and forecast, by Clinical Trial Phase
8.3.6.5.4 Market size and forecast, by End User
8.3.6.6 Rest of Europe
8.3.6.6.1 Market size and forecast, by Product
8.3.6.6.2 Market size and forecast, by Delivery Mode
8.3.6.6.3 Market size and forecast, by Clinical Trial Phase
8.3.6.6.4 Market size and forecast, by End User
8.4 Asia-Pacific
8.4.1 Key trends and opportunities
8.4.2 Asia-Pacific Market size and forecast, by Product
8.4.3 Asia-Pacific Market size and forecast, by Delivery Mode
8.4.4 Asia-Pacific Market size and forecast, by Clinical Trial Phase
8.4.5 Asia-Pacific Market size and forecast, by End User
8.4.6 Asia-Pacific Market size and forecast, by country
8.4.6.1 Japan
8.4.6.1.1 Market size and forecast, by Product
8.4.6.1.2 Market size and forecast, by Delivery Mode
8.4.6.1.3 Market size and forecast, by Clinical Trial Phase
8.4.6.1.4 Market size and forecast, by End User
8.4.6.2 China
8.4.6.2.1 Market size and forecast, by Product
8.4.6.2.2 Market size and forecast, by Delivery Mode
8.4.6.2.3 Market size and forecast, by Clinical Trial Phase
8.4.6.2.4 Market size and forecast, by End User
8.4.6.3 India
8.4.6.3.1 Market size and forecast, by Product
8.4.6.3.2 Market size and forecast, by Delivery Mode
8.4.6.3.3 Market size and forecast, by Clinical Trial Phase
8.4.6.3.4 Market size and forecast, by End User
8.4.6.4 Australia
8.4.6.4.1 Market size and forecast, by Product
8.4.6.4.2 Market size and forecast, by Delivery Mode
8.4.6.4.3 Market size and forecast, by Clinical Trial Phase
8.4.6.4.4 Market size and forecast, by End User
8.4.6.5 South Korea
8.4.6.5.1 Market size and forecast, by Product
8.4.6.5.2 Market size and forecast, by Delivery Mode
8.4.6.5.3 Market size and forecast, by Clinical Trial Phase
8.4.6.5.4 Market size and forecast, by End User
8.4.6.6 Rest of Asia-Pacific
8.4.6.6.1 Market size and forecast, by Product
8.4.6.6.2 Market size and forecast, by Delivery Mode
8.4.6.6.3 Market size and forecast, by Clinical Trial Phase
8.4.6.6.4 Market size and forecast, by End User
8.5 LAMEA
8.5.1 Key trends and opportunities
8.5.2 LAMEA Market size and forecast, by Product
8.5.3 LAMEA Market size and forecast, by Delivery Mode
8.5.4 LAMEA Market size and forecast, by Clinical Trial Phase
8.5.5 LAMEA Market size and forecast, by End User
8.5.6 LAMEA Market size and forecast, by country
8.5.6.1 Brazil
8.5.6.1.1 Market size and forecast, by Product
8.5.6.1.2 Market size and forecast, by Delivery Mode
8.5.6.1.3 Market size and forecast, by Clinical Trial Phase
8.5.6.1.4 Market size and forecast, by End User
8.5.6.2 Saudi Arabia
8.5.6.2.1 Market size and forecast, by Product
8.5.6.2.2 Market size and forecast, by Delivery Mode
8.5.6.2.3 Market size and forecast, by Clinical Trial Phase
8.5.6.2.4 Market size and forecast, by End User
8.5.6.3 South Africa
8.5.6.3.1 Market size and forecast, by Product
8.5.6.3.2 Market size and forecast, by Delivery Mode
8.5.6.3.3 Market size and forecast, by Clinical Trial Phase
8.5.6.3.4 Market size and forecast, by End User
8.5.6.4 Rest of LAMEA
8.5.6.4.1 Market size and forecast, by Product
8.5.6.4.2 Market size and forecast, by Delivery Mode
8.5.6.4.3 Market size and forecast, by Clinical Trial Phase
8.5.6.4.4 Market size and forecast, by End User
CHAPTER 9: COMPANY LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Key developments
CHAPTER 10: COMPANY PROFILES
10.1 Advarra, Inc. (Bio Optronics, Inc.)
10.1.1 Company overview
10.1.2 Company snapshot
10.1.3 Operating business segments
10.1.4 Product portfolio
10.1.5 Business performance
10.1.6 Key strategic moves and developments
10.2 Anju Software, Inc.
10.2.1 Company overview
10.2.2 Company snapshot
10.2.3 Operating business segments
10.2.4 Product portfolio
10.2.5 Business performance
10.2.6 Key strategic moves and developments
10.3 Business Systems Integration AG
10.3.1 Company overview
10.3.2 Company snapshot
10.3.3 Operating business segments
10.3.4 Product portfolio
10.3.5 Business performance
10.3.6 Key strategic moves and developments
10.4 Castor EDC
10.4.1 Company overview
10.4.2 Company snapshot
10.4.3 Operating business segments
10.4.4 Product portfolio
10.4.5 Business performance
10.4.6 Key strategic moves and developments
10.5 Clario
10.5.1 Company overview
10.5.2 Company snapshot
10.5.3 Operating business segments
10.5.4 Product portfolio
10.5.5 Business performance
10.5.6 Key strategic moves and developments
10.6 Dassault Systemes (Medidata Solution, Inc.)
10.6.1 Company overview
10.6.2 Company snapshot
10.6.3 Operating business segments
10.6.4 Product portfolio
10.6.5 Business performance
10.6.6 Key strategic moves and developments
10.7 DataTrak International, Inc.
10.7.1 Company overview
10.7.2 Company snapshot
10.7.3 Operating business segments
10.7.4 Product portfolio
10.7.5 Business performance
10.7.6 Key strategic moves and developments
10.8 eClinical Solutions, Inc.
10.8.1 Company overview
10.8.2 Company snapshot
10.8.3 Operating business segments
10.8.4 Product portfolio
10.8.5 Business performance
10.8.6 Key strategic moves and developments
10.9 IBM Watson Health
10.9.1 Company overview
10.9.2 Company snapshot
10.9.3 Operating business segments
10.9.4 Product portfolio
10.9.5 Business performance
10.9.6 Key strategic moves and developments
10.10 MaxisIT Inc.
10.10.1 Company overview
10.10.2 Company snapshot
10.10.3 Operating business segments
10.10.4 Product portfolio
10.10.5 Business performance
10.10.6 Key strategic moves and developments
10.11 MedNet Solutions
10.11.1 Company overview
10.11.2 Company snapshot
10.11.3 Operating business segments
10.11.4 Product portfolio
10.11.5 Business performance
10.11.6 Key strategic moves and developments
10.12 Medrio, Inc.
10.12.1 Company overview
10.12.2 Company snapshot
10.12.3 Operating business segments
10.12.4 Product portfolio
10.12.5 Business performance
10.12.6 Key strategic moves and developments
10.13 Parexel International Corporation (Calyx)
10.13.1 Company overview
10.13.2 Company snapshot
10.13.3 Operating business segments
10.13.4 Product portfolio
10.13.5 Business performance
10.13.6 Key strategic moves and developments
10.14 Saama Technologies, Inc.
10.14.1 Company overview
10.14.2 Company snapshot
10.14.3 Operating business segments
10.14.4 Product portfolio
10.14.5 Business performance
10.14.6 Key strategic moves and developments
10.15 Signant Health (CRF Health Inc.)
10.15.1 Company overview
10.15.2 Company snapshot
10.15.3 Operating business segments
10.15.4 Product portfolio
10.15.5 Business performance
10.15.6 Key strategic moves and developments
10.16 veeva systems
10.16.1 Company overview
10.16.2 Company snapshot
10.16.3 Operating business segments
10.16.4 Product portfolio
10.16.5 Business performance
10.16.6 Key strategic moves and developments
10.17 Oracle Corporation
10.17.1 Company overview
10.17.2 Company snapshot
10.17.3 Operating business segments
10.17.4 Product portfolio
10.17.5 Business performance
10.17.6 Key strategic moves and developments
LIST OF TABLES
TABLE 1. GLOBAL ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 2. ECLINICAL SOLUTIONS MARKET SIZE, FOR ELECTRONIC DATA CAPTURE AND CLINICAL DATA MANAGEMENT SYSTEMS, BY REGION, 2021-2031 ($MILLION)
TABLE 3. ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC DATA CAPTURE AND CLINICAL DATA MANAGEMENT SYSTEMS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. ECLINICAL SOLUTIONS MARKET SIZE, FOR CLINICAL TRIAL MANAGEMENT SYSTEMS, BY REGION, 2021-2031 ($MILLION)
TABLE 5. ECLINICAL SOLUTIONS MARKET FOR CLINICAL TRIAL MANAGEMENT SYSTEMS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 6. ECLINICAL SOLUTIONS MARKET SIZE, FOR RANDOMIZATION AND TRIAL SUPPLY MANAGEMENT, BY REGION, 2021-2031 ($MILLION)
TABLE 7. ECLINICAL SOLUTIONS MARKET FOR RANDOMIZATION AND TRIAL SUPPLY MANAGEMENT, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 8. ECLINICAL SOLUTIONS MARKET SIZE, FOR ELECTRONIC CLINICAL OUTCOME ASSESSMENT, BY REGION, 2021-2031 ($MILLION)
TABLE 9. ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CLINICAL OUTCOME ASSESSMENT, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 10. ECLINICAL SOLUTIONS MARKET SIZE, FOR ELECTRONIC TRAIL MASTER FILES, BY REGION, 2021-2031 ($MILLION)
TABLE 11. ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC TRAIL MASTER FILES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 12. ECLINICAL SOLUTIONS MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 13. ECLINICAL SOLUTIONS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 14. GLOBAL ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2021-2031 ($MILLION)
TABLE 15. ECLINICAL SOLUTIONS MARKET SIZE, FOR WEB-HOSTED, BY REGION, 2021-2031 ($MILLION)
TABLE 16. ECLINICAL SOLUTIONS MARKET FOR WEB-HOSTED, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 17. ECLINICAL SOLUTIONS MARKET SIZE, FOR ON-PREMISE, BY REGION, 2021-2031 ($MILLION)
TABLE 18. ECLINICAL SOLUTIONS MARKET FOR ON-PREMISE, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 19. ECLINICAL SOLUTIONS MARKET SIZE, FOR CLOUD-BASED, BY REGION, 2021-2031 ($MILLION)
TABLE 20. ECLINICAL SOLUTIONS MARKET FOR CLOUD-BASED, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 21. GLOBAL ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2021-2031 ($MILLION)
TABLE 22. ECLINICAL SOLUTIONS MARKET SIZE, FOR PHASE I, BY REGION, 2021-2031 ($MILLION)
TABLE 23. ECLINICAL SOLUTIONS MARKET FOR PHASE I, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 24. ECLINICAL SOLUTIONS MARKET SIZE, FOR PHASE II, BY REGION, 2021-2031 ($MILLION)
TABLE 25. ECLINICAL SOLUTIONS MARKET FOR PHASE II, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 26. ECLINICAL SOLUTIONS MARKET SIZE, FOR PHASE III, BY REGION, 2021-2031 ($MILLION)
TABLE 27. ECLINICAL SOLUTIONS MARKET FOR PHASE III, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 28. ECLINICAL SOLUTIONS MARKET SIZE, FOR PHASE IV, BY REGION, 2021-2031 ($MILLION)
TABLE 29. ECLINICAL SOLUTIONS MARKET FOR PHASE IV, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 30. GLOBAL ECLINICAL SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 31. ECLINICAL SOLUTIONS MARKET SIZE, FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY REGION, 2021-2031 ($MILLION)
TABLE 32. ECLINICAL SOLUTIONS MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 33. ECLINICAL SOLUTIONS MARKET SIZE, FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021-2031 ($MILLION)
TABLE 34. ECLINICAL SOLUTIONS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 35. ECLINICAL SOLUTIONS MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 36. ECLINICAL SOLUTIONS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 37. ECLINICAL SOLUTIONS MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 38. NORTH AMERICA ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 39. NORTH AMERICA ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2021-2031 ($MILLION)
TABLE 40. NORTH AMERICA ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2021-2031 ($MILLION)
TABLE 41. NORTH AMERICA ECLINICAL SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 42. NORTH AMERICA ECLINICAL SOLUTIONS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 43. U.S. ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 44. U.S. ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2021-2031 ($MILLION)
TABLE 45. U.S. ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2021-2031 ($MILLION)
TABLE 46. U.S. ECLINICAL SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 47. CANADA ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 48. CANADA ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2021-2031 ($MILLION)
TABLE 49. CANADA ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2021-2031 ($MILLION)
TABLE 50. CANADA ECLINICAL SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 51. MEXICO ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 52. MEXICO ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2021-2031 ($MILLION)
TABLE 53. MEXICO ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2021-2031 ($MILLION)
TABLE 54. MEXICO ECLINICAL SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 55. EUROPE ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 56. EUROPE ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2021-2031 ($MILLION)
TABLE 57. EUROPE ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2021-2031 ($MILLION)
TABLE 58. EUROPE ECLINICAL SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 59. EUROPE ECLINICAL SOLUTIONS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 60. GERMANY ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 61. GERMANY ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2021-2031 ($MILLION)
TABLE 62. GERMANY ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2021-2031 ($MILLION)
TABLE 63. GERMANY ECLINICAL SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 64. FRANCE ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 65. FRANCE ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2021-2031 ($MILLION)
TABLE 66. FRANCE ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2021-2031 ($MILLION)
TABLE 67. FRANCE ECLINICAL SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 68. U.K. ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 69. U.K. ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2021-2031 ($MILLION)
TABLE 70. U.K. ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2021-2031 ($MILLION)
TABLE 71. U.K. ECLINICAL SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 72. ITALY ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 73. ITALY ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2021-2031 ($MILLION)
TABLE 74. ITALY ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2021-2031 ($MILLION)
TABLE 75. ITALY ECLINICAL SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 76. SPAIN ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 77. SPAIN ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2021-2031 ($MILLION)
TABLE 78. SPAIN ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2021-2031 ($MILLION)
TABLE 79. SPAIN ECLINICAL SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 80. REST OF EUROPE ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 81. REST OF EUROPE ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2021-2031 ($MILLION)
TABLE 82. REST OF EUROPE ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2021-2031 ($MILLION)
TABLE 83. REST OF EUROPE ECLINICAL SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 84. ASIA-PACIFIC ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 85. ASIA-PACIFIC ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2021-2031 ($MILLION)
TABLE 86. ASIA-PACIFIC ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2021-2031 ($MILLION)
TABLE 87. ASIA-PACIFIC ECLINICAL SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 88. ASIA-PACIFIC ECLINICAL SOLUTIONS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 89. JAPAN ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 90. JAPAN ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2021-2031 ($MILLION)
TABLE 91. JAPAN ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2021-2031 ($MILLION)
TABLE 92. JAPAN ECLINICAL SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 93. CHINA ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 94. CHINA ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2021-2031 ($MILLION)
TABLE 95. CHINA ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2021-2031 ($MILLION)
TABLE 96. CHINA ECLINICAL SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 97. INDIA ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 98. INDIA ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2021-2031 ($MILLION)
TABLE 99. INDIA ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2021-2031 ($MILLION)
TABLE 100. INDIA ECLINICAL SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 101. AUSTRALIA ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 102. AUSTRALIA ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2021-2031 ($MILLION)
TABLE 103. AUSTRALIA ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2021-2031 ($MILLION)
TABLE 104. AUSTRALIA ECLINICAL SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 105. SOUTH KOREA ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 106. SOUTH KOREA ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2021-2031 ($MILLION)
TABLE 107. SOUTH KOREA ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2021-2031 ($MILLION)
TABLE 108. SOUTH KOREA ECLINICAL SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 109. REST OF ASIA-PACIFIC ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 110. REST OF ASIA-PACIFIC ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2021-2031 ($MILLION)
TABLE 111. REST OF ASIA-PACIFIC ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2021-2031 ($MILLION)
TABLE 112. REST OF ASIA-PACIFIC ECLINICAL SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 113. LAMEA ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 114. LAMEA ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2021-2031 ($MILLION)
TABLE 115. LAMEA ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2021-2031 ($MILLION)
TABLE 116. LAMEA ECLINICAL SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 117. LAMEA ECLINICAL SOLUTIONS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 118. BRAZIL ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 119. BRAZIL ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2021-2031 ($MILLION)
TABLE 120. BRAZIL ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2021-2031 ($MILLION)
TABLE 121. BRAZIL ECLINICAL SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 122. SAUDI ARABIA ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 123. SAUDI ARABIA ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2021-2031 ($MILLION)
TABLE 124. SAUDI ARABIA ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2021-2031 ($MILLION)
TABLE 125. SAUDI ARABIA ECLINICAL SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 126. SOUTH AFRICA ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 127. SOUTH AFRICA ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2021-2031 ($MILLION)
TABLE 128. SOUTH AFRICA ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2021-2031 ($MILLION)
TABLE 129. SOUTH AFRICA ECLINICAL SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 130. REST OF LAMEA ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 131. REST OF LAMEA ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2021-2031 ($MILLION)
TABLE 132. REST OF LAMEA ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2021-2031 ($MILLION)
TABLE 133. REST OF LAMEA ECLINICAL SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 134.ADVARRA, INC. (BIO OPTRONICS, INC.): COMPANY SNAPSHOT
TABLE 135.ADVARRA, INC. (BIO OPTRONICS, INC.): OPERATING SEGMENTS
TABLE 136.ADVARRA, INC. (BIO OPTRONICS, INC.): PRODUCT PORTFOLIO
TABLE 137.ADVARRA, INC. (BIO OPTRONICS, INC.): NET SALES,
TABLE 138.ADVARRA, INC. (BIO OPTRONICS, INC.): KEY STRATERGIES
TABLE 139.ANJU SOFTWARE, INC.: COMPANY SNAPSHOT
TABLE 140.ANJU SOFTWARE, INC.: OPERATING SEGMENTS
TABLE 141.ANJU SOFTWARE, INC.: PRODUCT PORTFOLIO
TABLE 142.ANJU SOFTWARE, INC.: NET SALES,
TABLE 143.ANJU SOFTWARE, INC.: KEY STRATERGIES
TABLE 144.BUSINESS SYSTEMS INTEGRATION AG: COMPANY SNAPSHOT
TABLE 145.BUSINESS SYSTEMS INTEGRATION AG: OPERATING SEGMENTS
TABLE 146.BUSINESS SYSTEMS INTEGRATION AG: PRODUCT PORTFOLIO
TABLE 147.BUSINESS SYSTEMS INTEGRATION AG: NET SALES,
TABLE 148.BUSINESS SYSTEMS INTEGRATION AG: KEY STRATERGIES
TABLE 149.CASTOR EDC: COMPANY SNAPSHOT
TABLE 150.CASTOR EDC: OPERATING SEGMENTS
TABLE 151.CASTOR EDC: PRODUCT PORTFOLIO
TABLE 152.CASTOR EDC: NET SALES,
TABLE 153.CASTOR EDC: KEY STRATERGIES
TABLE 154.CLARIO: COMPANY SNAPSHOT
TABLE 155.CLARIO: OPERATING SEGMENTS
TABLE 156.CLARIO: PRODUCT PORTFOLIO
TABLE 157.CLARIO: NET SALES,
TABLE 158.CLARIO: KEY STRATERGIES
TABLE 159.DASSAULT SYSTEMES (MEDIDATA SOLUTION, INC.): COMPANY SNAPSHOT
TABLE 160.DASSAULT SYSTEMES (MEDIDATA SOLUTION, INC.): OPERATING SEGMENTS
TABLE 161.DASSAULT SYSTEMES (MEDIDATA SOLUTION, INC.): PRODUCT PORTFOLIO
TABLE 162.DASSAULT SYSTEMES (MEDIDATA SOLUTION, INC.): NET SALES,
TABLE 163.DASSAULT SYSTEMES (MEDIDATA SOLUTION, INC.): KEY STRATERGIES
TABLE 164.DATATRAK INTERNATIONAL, INC.: COMPANY SNAPSHOT
TABLE 165.DATATRAK INTERNATIONAL, INC.: OPERATING SEGMENTS
TABLE 166.DATATRAK INTERNATIONAL, INC.: PRODUCT PORTFOLIO
TABLE 167.DATATRAK INTERNATIONAL, INC.: NET SALES,
TABLE 168.DATATRAK INTERNATIONAL, INC.: KEY STRATERGIES
TABLE 169.ECLINICAL SOLUTIONS, INC.: COMPANY SNAPSHOT
TABLE 170.ECLINICAL SOLUTIONS, INC.: OPERATING SEGMENTS
TABLE 171.ECLINICAL SOLUTIONS, INC.: PRODUCT PORTFOLIO
TABLE 172.ECLINICAL SOLUTIONS, INC.: NET SALES,
TABLE 173.ECLINICAL SOLUTIONS, INC.: KEY STRATERGIES
TABLE 174.IBM WATSON HEALTH: COMPANY SNAPSHOT
TABLE 175.IBM WATSON HEALTH: OPERATING SEGMENTS
TABLE 176.IBM WATSON HEALTH: PRODUCT PORTFOLIO
TABLE 177.IBM WATSON HEALTH: NET SALES,
TABLE 178.IBM WATSON HEALTH: KEY STRATERGIES
TABLE 179.MAXISIT INC.: COMPANY SNAPSHOT
TABLE 180.MAXISIT INC.: OPERATING SEGMENTS
TABLE 181.MAXISIT INC.: PRODUCT PORTFOLIO
TABLE 182.MAXISIT INC.: NET SALES,
TABLE 183.MAXISIT INC.: KEY STRATERGIES
TABLE 184.MEDNET SOLUTIONS: COMPANY SNAPSHOT
TABLE 185.MEDNET SOLUTIONS: OPERATING SEGMENTS
TABLE 186.MEDNET SOLUTIONS: PRODUCT PORTFOLIO
TABLE 187.MEDNET SOLUTIONS: NET SALES,
TABLE 188.MEDNET SOLUTIONS: KEY STRATERGIES
TABLE 189.MEDRIO, INC.: COMPANY SNAPSHOT
TABLE 190.MEDRIO, INC.: OPERATING SEGMENTS
TABLE 191.MEDRIO, INC.: PRODUCT PORTFOLIO
TABLE 192.MEDRIO, INC.: NET SALES,
TABLE 193.MEDRIO, INC.: KEY STRATERGIES
TABLE 194.PAREXEL INTERNATIONAL CORPORATION (CALYX): COMPANY SNAPSHOT
TABLE 195.PAREXEL INTERNATIONAL CORPORATION (CALYX): OPERATING SEGMENTS
TABLE 196.PAREXEL INTERNATIONAL CORPORATION (CALYX): PRODUCT PORTFOLIO
TABLE 197.PAREXEL INTERNATIONAL CORPORATION (CALYX): NET SALES,
TABLE 198.PAREXEL INTERNATIONAL CORPORATION (CALYX): KEY STRATERGIES
TABLE 199.SAAMA TECHNOLOGIES, INC.: COMPANY SNAPSHOT
TABLE 200.SAAMA TECHNOLOGIES, INC.: OPERATING SEGMENTS
TABLE 201.SAAMA TECHNOLOGIES, INC.: PRODUCT PORTFOLIO
TABLE 202.SAAMA TECHNOLOGIES, INC.: NET SALES,
TABLE 203.SAAMA TECHNOLOGIES, INC.: KEY STRATERGIES
TABLE 204.SIGNANT HEALTH (CRF HEALTH INC.): COMPANY SNAPSHOT
TABLE 205.SIGNANT HEALTH (CRF HEALTH INC.): OPERATING SEGMENTS
TABLE 206.SIGNANT HEALTH (CRF HEALTH INC.): PRODUCT PORTFOLIO
TABLE 207.SIGNANT HEALTH (CRF HEALTH INC.): NET SALES,
TABLE 208.SIGNANT HEALTH (CRF HEALTH INC.): KEY STRATERGIES
TABLE 209.VEEVA SYSTEMS: COMPANY SNAPSHOT
TABLE 210.VEEVA SYSTEMS: OPERATING SEGMENTS
TABLE 211.VEEVA SYSTEMS: PRODUCT PORTFOLIO
TABLE 212.VEEVA SYSTEMS: NET SALES,
TABLE 213.VEEVA SYSTEMS: KEY STRATERGIES
TABLE 214.ORACLE CORPORATION: COMPANY SNAPSHOT
TABLE 215.ORACLE CORPORATION: OPERATING SEGMENTS
TABLE 216.ORACLE CORPORATION: PRODUCT PORTFOLIO
TABLE 217.ORACLE CORPORATION: NET SALES,
TABLE 218.ORACLE CORPORATION: KEY STRATERGIES
LIST OF FIGURES
FIGURE 1.ECLINICAL SOLUTIONS MARKET SEGMENTATION
FIGURE 2.ECLINICAL SOLUTIONS MARKET,2021-2031
FIGURE 3.ECLINICAL SOLUTIONS MARKET,2021-2031
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.ECLINICAL SOLUTIONS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 12.ECLINICAL SOLUTIONS MARKET,BY PRODUCT,2021(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ELECTRONIC DATA CAPTURE AND CLINICAL DATA MANAGEMENT SYSTEMS ECLINICAL SOLUTIONS MARKET,2021-2031(%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF CLINICAL TRIAL MANAGEMENT SYSTEMS ECLINICAL SOLUTIONS MARKET,2021-2031(%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF RANDOMIZATION AND TRIAL SUPPLY MANAGEMENT ECLINICAL SOLUTIONS MARKET,2021-2031(%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF ELECTRONIC CLINICAL OUTCOME ASSESSMENT ECLINICAL SOLUTIONS MARKET,2021-2031(%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF ELECTRONIC TRAIL MASTER FILES ECLINICAL SOLUTIONS MARKET,2021-2031(%)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF OTHERS ECLINICAL SOLUTIONS MARKET,2021-2031(%)
FIGURE 19.ECLINICAL SOLUTIONS MARKET,BY DELIVERY MODE,2021(%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF WEB-HOSTED ECLINICAL SOLUTIONS MARKET,2021-2031(%)
FIGURE 21.COMPARATIVE SHARE ANALYSIS OF ON-PREMISE ECLINICAL SOLUTIONS MARKET,2021-2031(%)
FIGURE 22.COMPARATIVE SHARE ANALYSIS OF CLOUD-BASED ECLINICAL SOLUTIONS MARKET,2021-2031(%)
FIGURE 23.ECLINICAL SOLUTIONS MARKET,BY CLINICAL TRIAL PHASE,2021(%)
FIGURE 24.COMPARATIVE SHARE ANALYSIS OF PHASE I ECLINICAL SOLUTIONS MARKET,2021-2031(%)
FIGURE 25.COMPARATIVE SHARE ANALYSIS OF PHASE II ECLINICAL SOLUTIONS MARKET,2021-2031(%)
FIGURE 26.COMPARATIVE SHARE ANALYSIS OF PHASE III ECLINICAL SOLUTIONS MARKET,2021-2031(%)
FIGURE 27.COMPARATIVE SHARE ANALYSIS OF PHASE IV ECLINICAL SOLUTIONS MARKET,2021-2031(%)
FIGURE 28.ECLINICAL SOLUTIONS MARKET,BY END USER,2021(%)
FIGURE 29.COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES ECLINICAL SOLUTIONS MARKET,2021-2031(%)
FIGURE 30.COMPARATIVE SHARE ANALYSIS OF CONTRACT RESEARCH ORGANIZATIONS ECLINICAL SOLUTIONS MARKET,2021-2031(%)
FIGURE 31.COMPARATIVE SHARE ANALYSIS OF OTHERS ECLINICAL SOLUTIONS MARKET,2021-2031(%)
FIGURE 32.ECLINICAL SOLUTIONS MARKET BY REGION,2021
FIGURE 33.U.S. ECLINICAL SOLUTIONS MARKET,2021-2031($MILLION)
FIGURE 34.CANADA ECLINICAL SOLUTIONS MARKET,2021-2031($MILLION)
FIGURE 35.MEXICO ECLINICAL SOLUTIONS MARKET,2021-2031($MILLION)
FIGURE 36.GERMANY ECLINICAL SOLUTIONS MARKET,2021-2031($MILLION)
FIGURE 37.FRANCE ECLINICAL SOLUTIONS MARKET,2021-2031($MILLION)
FIGURE 38.U.K. ECLINICAL SOLUTIONS MARKET,2021-2031($MILLION)
FIGURE 39.ITALY ECLINICAL SOLUTIONS MARKET,2021-2031($MILLION)
FIGURE 40.SPAIN ECLINICAL SOLUTIONS MARKET,2021-2031($MILLION)
FIGURE 41.REST OF EUROPE ECLINICAL SOLUTIONS MARKET,2021-2031($MILLION)
FIGURE 42.JAPAN ECLINICAL SOLUTIONS MARKET,2021-2031($MILLION)
FIGURE 43.CHINA ECLINICAL SOLUTIONS MARKET,2021-2031($MILLION)
FIGURE 44.INDIA ECLINICAL SOLUTIONS MARKET,2021-2031($MILLION)
FIGURE 45.AUSTRALIA ECLINICAL SOLUTIONS MARKET,2021-2031($MILLION)
FIGURE 46.SOUTH KOREA ECLINICAL SOLUTIONS MARKET,2021-2031($MILLION)
FIGURE 47.REST OF ASIA-PACIFIC ECLINICAL SOLUTIONS MARKET,2021-2031($MILLION)
FIGURE 48.BRAZIL ECLINICAL SOLUTIONS MARKET,2021-2031($MILLION)
FIGURE 49.SAUDI ARABIA ECLINICAL SOLUTIONS MARKET,2021-2031($MILLION)
FIGURE 50.SOUTH AFRICA ECLINICAL SOLUTIONS MARKET,2021-2031($MILLION)
FIGURE 51.REST OF LAMEA ECLINICAL SOLUTIONS MARKET,2021-2031($MILLION)
FIGURE 52. TOP WINNING STRATEGIES, BY YEAR
FIGURE 53. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 54. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 55.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 56.COMPETITIVE DASHBOARD
FIGURE 57.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 58.ADVARRA, INC. (BIO OPTRONICS, INC.).: NET SALES ,($MILLION)
FIGURE 59.ANJU SOFTWARE, INC..: NET SALES ,($MILLION)
FIGURE 60.BUSINESS SYSTEMS INTEGRATION AG.: NET SALES ,($MILLION)
FIGURE 61.CASTOR EDC.: NET SALES ,($MILLION)
FIGURE 62.CLARIO.: NET SALES ,($MILLION)
FIGURE 63.DASSAULT SYSTEMES (MEDIDATA SOLUTION, INC.).: NET SALES ,($MILLION)
FIGURE 64.DATATRAK INTERNATIONAL, INC..: NET SALES ,($MILLION)
FIGURE 65.ECLINICAL SOLUTIONS, INC..: NET SALES ,($MILLION)
FIGURE 66.IBM WATSON HEALTH.: NET SALES ,($MILLION)
FIGURE 67.MAXISIT INC..: NET SALES ,($MILLION)
FIGURE 68.MEDNET SOLUTIONS.: NET SALES ,($MILLION)
FIGURE 69.MEDRIO, INC..: NET SALES ,($MILLION)
FIGURE 70.PAREXEL INTERNATIONAL CORPORATION (CALYX).: NET SALES ,($MILLION)
FIGURE 71.SAAMA TECHNOLOGIES, INC..: NET SALES ,($MILLION)
FIGURE 72.SIGNANT HEALTH (CRF HEALTH INC.).: NET SALES ,($MILLION)
FIGURE 73.VEEVA SYSTEMS.: NET SALES ,($MILLION)
FIGURE 74.ORACLE CORPORATION.: NET SALES ,($MILLION)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security